Quotient Sciences, a global integrated contract research, development and manufacturing organisation (CRDMO), and Acesion Pharma, a biotech company developing treatments for cardiac arrhythmia, are collaborating to apply Quotient Sciences’ AI-enhanced formulation development solution within its Translational Pharmaceutics platform.
The collaboration supports Acesion’s early-stage pipeline of small molecules targeting atrial fibrillation, the world’s most common sustained cardiac arrhythmia.
Quotient Sciences’ AI-enhanced formulation development solution applies active machine learning (ML) with Bayesian optimisation to identify and prioritise the drug products most likely to succeed in the clinic, helping partners make faster, better-informed decisions earlier in development.
Atrial fibrillation
The lifetime risk of developing atrial fibrillation is one in three adults over age 55, making it one of the most common cardiovascular disorders associated with age.
Patients with atrial fibrillation face a five-fold increased risk of stroke, making effective management critical for reducing serious complications. An estimated 50-60 million people worldwide are impacted by Atrial fibrillation.
AI-enhanced formulation development within Translational Pharmaceutics
Quotient Sciences’ Translational Pharmaceutics platform optimises drug development by integrating a range of drug product formulation and clinical activities. Biotech and pharmaceutical companies globally have used it for more than 20 years as a proven method for advancing candidates through early development.
Translational Pharmaceutics has been enhanced with Quotient Sciences’ new AI-enhanced formulation development solution, allowing development teams to analyse data and predict formulation performance earlier and more precisely, shortening development timelines while supporting better-informed decisions. Early development activities can focus on drug product candidates with the highest chances of clinical success.
Dr Andrew Lewis, chief scientific officer at Quotient Sciences, said, “This collaboration with Acesion Pharma reflects exactly what our AI-enhanced formulation development solution, combined with Translational Pharmaceutics, is designed to deliver: helping our partners make better-informed, faster decisions about their drug product formulations. We’re proud to be working with Acesion on a shared commitment to innovation, and to support their pipeline in the field of atrial fibrillation.”
Dr Elisabeth V. Carstensen, vice president, CMC, at Acesion Pharma said, “We are excited to, together with Quotient Sciences, explore how their AI-enhanced algorithms can help guide and accelerate oral formulation development for our small-molecule compounds. By helping to guide and accelerate development decisions, this approach has the potential to shorten timelines for clinical testing and increase the likelihood of achieving the desired product profile.”
